When obesity meds get blamed in the OR
A perioperative review argues that adverse effects from modern anti-obesity drugs can be mistaken for surgical or anesthesia complications, raising the bar for documentation, holds, and post-op restarts.
The perioperative conversation around anti-obesity medications has been dominated by one question: do glucagon-like peptide‑1 (GLP‑1) receptor agonists slow gastric emptying enough to change aspiration risk? That framing made sense when these drugs were “new enough” that hospitals were still writing the first checklists.
Now there’s a different problem showing up in the background noise of real clinical work: attribution. When a post-op patient has abdominal pain, vomiting, an unexpected CT finding, or a neuropsychiatric change, the team has to decide what is a surgical complication, what is an anesthesia complication, and what might be a medication effect. In a world where anti-obesity medications are increasingly common, those categories can blur.
A narrative review in Korean Journal of Anesthesiology makes that argument explicitly and puts a name on it: the “misidentification trap,” where drug adverse effects can be clinically and radiographically hard to distinguish from perioperative harm, and the clinician who gets blamed may be the person closest to the event, not the true cause. The paper is Blamed but not at fault: Anti-obesity medication adverse effects misidentified as perioperative complications (2026).
The perioperative risk story is bigger than aspiration
The review’s core complaint is that guidelines have tended to focus narrowly on GLP‑1 receptor agonists and aspiration risk. That leaves two gaps.
First, it misses a set of adverse effects that are rare but high-stakes when they happen in the immediate post-op window. The paper highlights examples that are easy to imagine being misattributed in the heat of postoperative decision-making: pancreatitis, bowel obstruction (including scenarios tied to premature post-op restart), vision loss signals, and neuropsychiatric effects that could be confused with emergence phenomena.
Second, it underplays the fact that the modern “anti-obesity medication” category is broader than GLP‑1 drugs. In the same pre-op medication list you may see dual glucose-dependent insulinotropic polypeptide (GIP)/GLP‑1 agonists such as tirzepatide, and non-incretin agents like orlistat, phentermine, or bupropion/naltrexone. If perioperative processes are written as if the only relevant exposure is “weekly semaglutide,” they will miss patients.
Why the misidentification trap matters in practice
In a courtroom, the story often collapses into a clean narrative with a single villain. In real medicine, the story is a mess of timing, overlapping symptoms, and imperfect information.
The “misidentification trap” is not a claim that anti-obesity drugs explain every postoperative problem. It’s a reminder that some drug-related adverse effects can look like classic perioperative complications. When the bedside signal is ambiguous, teams can end up on the wrong branch of the decision tree: unnecessary imaging, unnecessary antibiotics, and in the worst case, unnecessary re-intervention.
The review even treats documentation as patient safety infrastructure, not just paperwork. If the medication history is incomplete, or if a post-op hold is not written in a way that survives handoffs, the default is that someone restarts the medication at the first sign of “back to normal.” That can be a reasonable choice in many patients, but the paper argues that doing it automatically is where trouble starts.
A conservative take: more structured handoffs, fewer confident assumptions
The most actionable recommendation in the review is boring by design: structured preoperative anti-obesity medication documentation, explicit postoperative hold orders, and a habit of including medication effects in the differential diagnosis when new symptoms appear after surgery.
That won’t eliminate adverse effects and it won’t eliminate surgical complications. But it does change the odds that the team asks the right question early: “Is this a complication of the operation, a complication of anesthesia, or could this be a medication signal wearing the wrong mask?”
What would actually move the evidence forward
A narrative review can name the pattern, but it can’t tell you the base rate. What would genuinely clarify the risk is prospective perioperative tracking: which patients were on which anti-obesity medications, what hold and restart patterns were used, and how postoperative complications were adjudicated when symptoms could fit multiple causes.
Until then, the paper’s takeaway is mostly about humility. The era of pharmacologic obesity management is now baked into routine care, and perioperative teams will increasingly be asked to distinguish “iatrogenic injury” from “drug effect” in real time, with imperfect information.